/

Sociétés

Da

Non vérifié

Daiichi Sankyo

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

98 communiqués de presse

Voir tous les communiqués de presse

31/07/2026

Web et Réseaux Sociaux

Téléphonie et Divers

Marché financier

Science

Médecine - Divers

Santé Publique

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Source

Émetteur

1.00

0

31/07/2026

Marché du travail

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Source

Émetteur

1.00

0

24/07/2026

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Source

Émetteur

1.00

0

29/06/2026

Oncologie

Santé

Biotechnologie

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Industrie

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Source

Émetteur

1.00

0

26/06/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Source

Émetteur

1.00

0

28/05/2026

Événements

Industrie

Science

Biotechnologie

Médecine - Divers

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

Source

Émetteur

1.00

0

22/05/2026

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé Publique

Santé

Hygiène alimentaire

Médecine - Divers

Industrie

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Source

Émetteur

1.00

0

22/05/2026

Oncologie

Santé

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Marché du travail

Industrie

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Source

Émetteur

1.00

0

15/05/2026

Industrie

Oncologie

Santé

Hygiène alimentaire

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

Source

Émetteur

1.00

0

11/05/2026

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0